Fig. 2.
General workflow of 203/212Pb pre-concentration and elution for radiolabeling of chelator-modified bioconjugates: (2-A1) Pre-concentration of 203/212Pb2+ on the Pb-specific cartridge; (2-A2) Removal of metallic interferences with a HNO3 rinse; (2-A3) Elution of the purified/pre-concentrated 203/212Pb2+ by NaOAc buffer to the radiolabeling vessel containing chelator-modified bioconjugates; (B) Molecular structure of DOTATOC used for this study; (C) Molecular structure of DOTA-PEG4-VMT-MCR1 used for this study.